Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study

The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study

Jeanne C Latourelle et al. BMC Med. .

Abstract

Background: We report age-dependent penetrance estimates for leucine-rich repeat kinase 2 (LRRK2)-related Parkinson's disease (PD) in a large sample of familial PD. The most frequently seen LRRK2 mutation, Gly2019Ser (G2019S), is associated with approximately 5 to 6% of familial PD cases and 1 to 2% of idiopathic cases, making it the most common known genetic cause of PD. Studies of the penetrance of LRRK2 mutations have produced a wide range of estimates, possibly due to differences in study design and recruitment, including in particular differences between samples of familial PD versus sporadic PD.

Methods: A sample, including 903 affected and 58 unaffected members from 509 families ascertained for having two or more PD-affected members, 126 randomly ascertained PD patients and 197 controls, was screened for five different LRRK2 mutations. Penetrance was estimated in families of LRRK2 carriers with consideration of the inherent bias towards increased penetrance in a familial sample.

Results: Thirty-one out of 509 families with multiple cases of PD (6.1%) were found to have 58 LRRK2 mutation carriers (6.4%). Twenty-nine of the 31 families had G2019S mutations while two had R1441C mutations. No mutations were identified among controls or unaffected relatives of PD cases. Nine PD-affected relatives of G2019S carriers did not carry the LRRK2 mutation themselves. At the maximum observed age range of 90 to 94 years, the unbiased estimated penetrance was 67% for G2019S families, compared with a baseline PD risk of 17% seen in the non-LRRK2-related PD families.

Conclusion: Lifetime penetrance of LRRK2 estimated in the unascertained relatives of multiplex PD families is greater than that reported in studies of sporadically ascertained LRRK2 cases, suggesting that inherited susceptibility factors may modify the penetrance of LRRK2 mutations. In addition, the presence of nine PD phenocopies in the LRRK2 families suggests that these susceptibility factors may also increase the risk of non-LRRK2-related PD. No differences in penetrance were found between men and women, suggesting that the factors that influence penetrance for LRRK2 carriers are independent of the factors which increase PD prevalence in men.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The box plot shows the median and 25th and 75th percentiles with whiskers extending to the 5th and 95th percentiles of the penetrance at each age range for G2019S carriers and for non-LRRK2 carriers among families recruited for at least two Parkinson's disease-affected siblings.

Comment in

Similar articles

Cited by

  • Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson's disease.
    Turski P, Chaberska I, Szukało P, Pyska P, Milanowski Ł, Szlufik S, Figura M, Hoffman-Zacharska D, Siuda J, Koziorowski D. Turski P, et al. Front Neurosci. 2022 Sep 20;16:971270. doi: 10.3389/fnins.2022.971270. eCollection 2022. Front Neurosci. 2022. PMID: 36203807 Free PMC article. Review.
  • Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation.
    Berger Z, Smith KA, Lavoie MJ. Berger Z, et al. Biochemistry. 2010 Jul 6;49(26):5511-23. doi: 10.1021/bi100157u. Biochemistry. 2010. PMID: 20515039 Free PMC article.
  • The genetics of Parkinson's disease: progress and therapeutic implications.
    Singleton AB, Farrer MJ, Bonifati V. Singleton AB, et al. Mov Disord. 2013 Jan;28(1):14-23. doi: 10.1002/mds.25249. Mov Disord. 2013. PMID: 23389780 Free PMC article. Review.
  • Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease.
    Blauwendraat C, Kia DA, Pihlstrøm L, Gan-Or Z, Lesage S, Gibbs JR, Ding J, Alcalay RN, Hassin-Baer S, Pittman AM, Brooks J, Edsall C, Chung SJ, Goldwurm S, Toft M, Schulte C; International Parkinson's Disease Genomics Consortium (IPDGC), COURAGE-PD Consortium; Hernandez D, Singleton AB, Nalls MA, Brice A, Scholz SW, Wood NW. Blauwendraat C, et al. Neurobiol Aging. 2018 Apr;64:159.e5-159.e8. doi: 10.1016/j.neurobiolaging.2017.12.012. Epub 2017 Dec 20. Neurobiol Aging. 2018. PMID: 29398121 Free PMC article.
  • Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.
    Lai D, Alipanahi B, Fontanillas P, Schwantes-An TH, Aasly J, Alcalay RN, Beecham GW, Berg D, Bressman S, Brice A, Brockman K, Clark L, Cookson M, Das S, Van Deerlin V, Follett J, Farrer MJ, Trinh J, Gasser T, Goldwurm S, Gustavsson E, Klein C, Lang AE, Langston JW, Latourelle J, Lynch T, Marder K, Marras C, Martin ER, McLean CY, Mejia-Santana H, Molho E, Myers RH, Nuytemans K, Ozelius L, Payami H, Raymond D, Rogaeva E, Rogers MP, Ross OA, Samii A, Saunders-Pullman R, Schüle B, Schulte C, Scott WK, Tanner C, Tolosa E, Tomkins JE, Vilas D, Trojanowski JQ; 23andMe Research Team; Uitti R, Vance JM, Visanji NP, Wszolek ZK, Zabetian CP, Mirelman A, Giladi N, Orr Urtreger A, Cannon P, Fiske B, Foroud T. Lai D, et al. Ann Neurol. 2021 Jul;90(1):76-88. doi: 10.1002/ana.26094. Epub 2021 May 17. Ann Neurol. 2021. PMID: 33938021 Free PMC article.

References

    1. Mayeux R. Epidemiology of neurodegeneration. Annual review of neuroscience. 2003;26:81–104. doi: 10.1146/annurev.neuro.26.043002.094919. - DOI - PubMed
    1. Tan EK, Skipper LM. Pathogenic mutations in Parkinson disease. Human mutation. 2007;28:641–653. doi: 10.1002/humu.20507. - DOI - PubMed
    1. Singleton AB. Altered alpha-synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin. Trends in neurosciences. 2005;28:416–421. doi: 10.1016/j.tins.2005.05.009. - DOI - PubMed
    1. Funayama M, Hasegawa K, Kowa H, Saito M, Tsuji S, Obata F. A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Annals of neurology. 2002;51:296–301. doi: 10.1002/ana.10113. - DOI - PubMed
    1. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, Brug M van der, Lopez de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Marti-Masso JF, Perez-Tur J, Wood NW, Singleton AB. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron. 2004;44:595–600. doi: 10.1016/j.neuron.2004.10.023. - DOI - PubMed

Publication types